CRISPR Therapeutics
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
| Formerly | Inception Genomics |
|---|---|
| Company type | Public |
Traded as | Nasdaq: CRSP |
| ISIN | CH0334081137 |
| Industry | Biotechnology |
| Founded | 2013 |
| Founders |
|
| Headquarters | Zug, Switzerland |
Key people | Samarth Kulkarni (CEO) |
| Revenue | US$371 million (2023) |
| US$−223 million (2023) | |
Net income | US$−154 million (2023) |
| Total assets | US$2.23 billion (2023) |
| Total equity | US$1.88 billion (2023) |
Number of employees | 407 (2023) |
| Website | crisprtx |
| Footnotes / references | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.